Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Bootmaker Dr Martens hit by weak December as US sales slide

Published 25/01/2024, 07:33
Updated 25/01/2024, 11:20
© Reuters. Dr. Martens logos are pictured in Manchester, Britain, May 26, 2023. REUTERS/Jason Cairnduff

By Eva Mathews

(Reuters) -Britain's Dr Martens (LON:DOCS) said its visibility over wholesale orders "remains weak" as the bootmaker posted a drop in third-quarter revenue on Thursday following several profit warnings and a disappointing December trading period.

The company, known for its clunky boots with yellow stitching, also said current Red Sea shipping diversions were adding to journey times and costs for supplies.

Dr Martens posted a drop of 21% in revenue to 267.1 million pounds ($340 million) for the three months ended Dec. 31, compared with 273.8 million pounds in the same period last year.

In November, Dr Martens issued its fourth profit warning in 12 months as it struggles with customer destocking and reduced orders in the United States from wholesale customers wary of macroeconomic pressures. For the quarter, Americas revenue was down 31% on a reported basis.

More recent concerns for retailers centre around efforts by global shipping firms to avoid the Red Sea that leads to the Suez Canal due to attacks on vessels by Houthi militants in Yemen. Ships diverting around Africa's Cape of Good Hope are adding around two weeks to journey times and extra costs.

CEO Kenny Wilson said the company, which has a contract with Danish shipping group Maersk, was currently seeing an impact of 12 days on shipping, which would have cost implications. He did not specify how much additional cost was expected nor comment on whether those costs would be passed on to consumers.

"Wholesale customers continue to have relatively low levels of in-market inventory, however the timing and level of re-orders is unpredictable, meaning that our visibility over wholesale remains weak," the company said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Shares in Dr Martens, which made its market debut in 2021 with a market capitalisation of $5 billion, were up 6.7% to 80.40 pence at 1020 GMT, having more than halved in 2023.

"Today’s trading update effectively confirmed the downgrades announced previously, with the shares seeing a small relief bounce in response to no further changes to trading expectations," said John Stevenson, Peel Hunt (LON:PEEL) analyst.

($1 = 0.7859 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.